Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Main subject
Language
Document Type
Year range
1.
researchsquare; 2022.
Preprint in English | PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-2122106.v1

ABSTRACT

The novel coronavirus pandemic continues to cause significant morbidity and mortality around the world. Diverse clinical presentations prompted numerous attempts to predict disease severity to improve care and patient outcomes. Equally important is understanding the mechanisms underlying such divergent disease outcome. Multivariate modeling was used here to define the most distinctive features that separate COVID-19 from healthy controls and those that separate severe from moderate disease. Using discriminant analysis and binary logistic regression models we could distinguish between COVID-19 patients with severe disease, those with moderate disease, and controls with rates of correct classifications ranging from 71-100%. The distinction of severe and moderate disease was most reliant on the depletion of natural killer cells and activated, class-switched memory B cells, increased frequency of neutrophils, and decreased expression of the activation marker HLA-DR on monocytes in patients suffering from severe disease. In patients with moderate disease compared to those with severe disease and controls, we see increased frequency of activated class-switched memory B cells and activated neutrophils. Our results suggest that natural killer cells, activated class-switched memory B cells, and activated neutrophils are important for protection against severe disease. We show that binary logistic regression was superior to discriminant analysis by attaining higher rates of correct classification based on immune profiles. We discuss the utility of these multivariate techniques in biomedical sciences, contrast their mathematical basis and limitations, and propose strategies to overcome such limitations.


Subject(s)
COVID-19
SELECTION OF CITATIONS
SEARCH DETAIL